|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||31.07|
|Forward Dividend & Yield||2.73 (3.19%)|
|1y Target Est||N/A|
The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.
In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment.
Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take i...
Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.
Swiss drugmaker Novartis AG plans to reduce or drop production of some generic drugs and will close its 450-employee Sandoz plant in Broomfield over the next two years as a result. The Sandoz facility has been in Broomfield for 42 years. Novartis (NVS) plans to consolidate production of drug ingredients at a sister plant in Wilson, North Carolina, and shut down the Broomfield manufacturing plant by the end of 2019, the company said.
Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures. "To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated markets," a company spokesman said on Thursday. The shutdown of Novartis's Sandoz division plant in the Denver suburb of Broomfield was originally reported by the Denver Post.
Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients.
U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer. The Food and Drug Administration approved the gene therapy, to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.
The Food and Drug Administration just approved Yescarta, a treatment that genetically modifies a patient's own white cells to battle lymphoma. The price? $373,000.
Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung. "We said we would review whether it makes sense to sell the stake," Reinhardt told the newspaper. In May 2016, Chief Executive Officer Joe Jimenez said he was ready to sell the Roche stake without demanding a premium and that Novartis has been discussing options with banks.
Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer.
Credit Suisse Lilly’s Verzenio (abemaciclib) has obtained Food and Drug Administration approval for use in patients with HR+, HER2- metastatic breast cancer who progressed on prior therapy. Given the data that we have seen for Lilly’s (LLY) product from the MONARCH-1 and MONARCH-2 studies, we had expected the approval, although it does comes three to four months earlier than we had expected, representing another example of the agency working to get innovative products to the market quickly. Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy in patients with metastatic disease.
Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.
Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model.
Advanced Accelerator Applications launched to a record high Thursday on rumors Novartis could attempt to take it over.
Novartis's research head expects an alliance with a University of California chemistry lab to produce drug candidates within three years as the Swiss company accelerates its hunt for new medicines. Novartis announced the Novartis-Berkeley Center for Proteomics and Chemistry Technologies on Thursday. Basel-based Novartis hopes Berkeley scientists including Daniel Nomura, the professor who runs the lab, will speed its search for the Achilles' heels of hard-to-treat diseases.